These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31060912)

  • 1. B7-H3 and its role in bone cancers.
    He L; Li Z
    Pathol Res Pract; 2019 Jun; 215(6):152420. PubMed ID: 31060912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
    Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
    Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis.
    Wang L; Zhang Q; Chen W; Shan B; Ding Y; Zhang G; Cao N; Liu L; Zhang Y
    PLoS One; 2013; 8(8):e70689. PubMed ID: 23940627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCĪ± activation.
    Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
    J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
    Guo X; Chang M; Wang Y; Xing B; Ma W
    Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
    Yang S; Wei W; Zhao Q
    Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switchable CAR T cell strategy against osteosarcoma.
    Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
    Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells.
    Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C
    Front Immunol; 2021; 12():691741. PubMed ID: 34211478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
    Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
    Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
    BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of B7-H3 in cancer tissue during osteosarcoma progression in nude mice.
    Yin SJ; Wang WJ; Zhang JY
    Genet Mol Res; 2015 Nov; 14(4):14253-61. PubMed ID: 26600483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
    Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
    Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
    Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
    J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of B7-H3 in tumors and its potential in clinical application.
    Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.
    Wang L; Kang FB; Sun N; Wang J; Chen W; Li D; Shan BE
    Tumour Biol; 2016 Nov; 37(11):14939-14947. PubMed ID: 27644254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.